KOREA UNITED PHARM. INC.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Drug-drug Interaction Study Between UIC201603, and UIC201604

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: UIC201603 and co-administration of UIC201603 and UIC201604
Drug: UIC201604 and co-administration of UIC201603 and UIC201604

First Posted Date: 2024-08-23

Last Posted Date: 2024-08-23

Lead Sponsor: Korea United Pharm. Inc.

Target Recruit Count: 57

Registration Number: NCT06568133

Locations: 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of

A Study to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UI059 and UIC202201

Phase 1

Not yet recruiting

Conditions: Gastro-Intestinal Disorder

Interventions: Drug: UI059
Drug: UIC202201

First Posted Date: 2024-05-01

Last Posted Date: 2024-05-01

Lead Sponsor: Korea United Pharm. Inc.

Target Recruit Count: 66

Registration Number: NCT06393881

Locations: 🇰🇷
Chungbuk national university hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of

A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects

Phase 1

Completed

Conditions: GERD

Interventions: Drug: UI059
Drug: UIC202201

First Posted Date: 2023-11-21

Last Posted Date: 2023-11-21

Lead Sponsor: Korea United Pharm. Inc.

Target Recruit Count: 8

Registration Number: NCT06141577

Locations: 🇰🇷
Chungbuk national university hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of

A Clinical Study to Evaluate the Safety and the Pharmacokinetics of UI068 in Healthy Adult Volunteers Under Fed Conditions

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: administration of UI068
Drug: administration of UIC202205, UIC202206

First Posted Date: 2023-11-21

Last Posted Date: 2023-11-21

Lead Sponsor: Korea United Pharm. Inc.

Target Recruit Count: 35

Registration Number: NCT06141590

Locations: 🇰🇷
H plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of

A Study to Compare PK, PD and Safety of UI058 and UIC202004 in Healthy Subjects

Phase 1

Completed

Conditions: GERD

Interventions: Drug: administration of UI058
Drug: administration of UIC202004

First Posted Date: 2022-03-16

Last Posted Date: 2024-07-03

Lead Sponsor: Korea United Pharm. Inc.

Target Recruit Count: 41

Registration Number: NCT05282914

Locations: 🇰🇷
Chungbuk national university hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of

Drug-drug Interaction Study Between UIC201601 and UIC201602

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: UIC201601 and co-administration of UIC201601 and UIC201602
Drug: UIC201602 and co-administration of UIC201601 and UIC201602

First Posted Date: 2022-01-13

Last Posted Date: 2022-01-13

Lead Sponsor: Korea United Pharm. Inc.

Target Recruit Count: 40

Registration Number: NCT05190133

Study to Evaluate the Safety and PK of UI018

Phase 1

Conditions: Hyperlipemia, Mixed

Interventions: Drug: co-administration of UIC201806 and UIC201602
Drug: administration of UI018

First Posted Date: 2021-10-20

Last Posted Date: 2021-12-21

Lead Sponsor: Korea United Pharm. Inc.

Target Recruit Count: 44

Registration Number: NCT05085184

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of

Arformoterol/Budesonide for COVID-19

Phase 2

Conditions: Coronavirus Infection

Interventions: Drug: UI030

First Posted Date: 2021-09-24

Last Posted Date: 2021-09-24

Lead Sponsor: Korea United Pharm. Inc.

Target Recruit Count: 140

Registration Number: NCT05055414

Safety and Efficacy of Cefecin Tab. in Patients With Acute Sinusitis

Phase 4

Terminated

Conditions: Acute Sinusitis

Interventions: Drug: Cefecin Tab.
Drug: Omnicef Cap.

First Posted Date: 2020-12-11

Last Posted Date: 2020-12-11

Lead Sponsor: Korea United Pharm. Inc.

Target Recruit Count: 284

Registration Number: NCT04664803

Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia

Phase 3

Completed

Conditions: Functional Dyspepsia

Interventions: Drug: UI05MSP015CT
Drug: Gasmotin

First Posted Date: 2017-07-21

Last Posted Date: 2017-07-21

Lead Sponsor: Korea United Pharm. Inc.

Target Recruit Count: 143

Registration Number: NCT03225248

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy